AFFIRMED PHARMA, LLC

Biotech · Private

Rusalatide acetate (TP508), a radio-mitigating therapeutic peptide for treating radiation-induced keratopathy

Grants
$730K
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
2
1 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · Rusalatide Acetate (TP508) Mitigation of Genotoxic Radiation Damage in Human Lens Epithelial Cells$327,510
Federal grantDepartment of Health and Human Services · Phase I · Rusalatide Acetate (TP508) Mitigation of Genotoxic Radiation Damage in Human Lens Epithelial Cells$61,263
Federal grantDepartment of Health and Human Services · Phase I · Rusalatide Acetate (TP508) Mitigation Effect on Radiation Induced Keratopathy$341,302
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2173LOKI THERAPEUTICS, INC——
2174Aruvant Sciences——
2175Arena Therapeutics OpCo, Inc.—$600K
2176AFFIRMED PHARMA, LLC——
2177PARTILLION BIOSCIENCE CORPORATION——
2178AVADIM HEALTH, INC.—$81M
2179ID4PHARMA, LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 2

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.